Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound
margin administered by intradermal injection following the excision of keloid scars on the
ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly
distressing for patients as they are very difficult to conceal and are usually bilateral. As
the recurrence rate and growth rate of keloids can vary significantly between individuals,
trial subjects will have bilateral ear lobe keloids and will act as their own control. One
ear lobe will be treated with Juvista following keloid excision and one with placebo.